Invicta Diagnostic IPO Subscription Status
Invicta Diagnostic IPO subscribed over 0.95x on its second day till 5.00 PM on December 2nd, 2025.
- The Invicta Diagnostic IPO subscription QIB investors’ portion is 1.55 times, while NII subscribed 0.74 times, and RII investors subscribed 0.79 times.
- The company has received bids for 22,30,400 shares against 23,44,000 shares on offer on the second day of subscription.
- Invicta Diagnostic’s IPO was subscribed over 0.95x on its day 2.
- Invicta Diagnostic’s IPO was subscribed over 0.54x on its day 1.
About Invicta Diagnostic Company
Invicta Diagnostic Limited has been engaged in providing radiology and pathology solutions since January 2021. Under the brand ‘PC Diagnostics’, the company provides pathology and radiology tests, including imaging and teleradiology. Invicta runs 7 diagnostic centres and a central lab across Mumbai, Maharashtra. As of October 31, 2025, the company provides a wide range of medical specialty tests, including 60 routine and 487 specialized pathology tests, along with 96 basic and 130 advanced radiology tests.
The company offers a wide range of pathology and radiology tests, such as biochemistry and clinical pathology, cytogenetics, and high-end molecular diagnostics, basic echocardiograms, X-rays, ultrasounds, CT scans, MRI scans, and PET CT scans. Moreover, the company also runs a hub-and-spoke model in the Mumbai Metropolitan Region with a main hub in Thane West, 3 additional hubs in Bhayandar, Byculla, and Marol, and 3 spokes in Lower Parel, Sewri, and Kalwa.
Invicta Diagnostic IPO GMP
Invicta Diagnostic IPO GMP was ₹0 as of Tuesday, 2nd December 2025. That indicates the IPO is trading at ₹85 with a ₹0 premium in the grey market against the issue price of ₹85.
